The aims of this double blind trial are to examine the effect of saffron syrup on labor pain severity and intensity of anxiety (primary outcomes) and duration of labor phases, hemoglobin, hematocrit, delivery experience score, woman satisfaction, amount of oxytocin used, and newborn bilirubin (secondary outcomes) in primiparous women. Ninety six low- risk women with gestational age of 38 to 41 weeks, referring to the 29 Bahman hospital in Tabriz, will be randomized into one of three groups: each receiving 80 to 240 ml syrup; containing 250 to 750 mg saffron and palm sugar, 250 to 750 mg saffron and artificial sugar, or placebo; using block randomization with block sizes of 3, 6 and 9, determined with a computerized program. A person not involved in the recruitment and data collection will determine allocation sequence and will number bottles containing the syrups identical in terms of color, taste and smell. After getting written informed consent and gathering baseline data, participants will take 80 ml of the syrup (made by Yashil drug company, Aras) when cervical dilation is around 3 to 4 cm and there are at least three uterine contractions in 10 minutes lasting for 45 to 60 seconds. It will be repeated every two hours for maximum three doses considering pain intensity, uterine contraction, and pattern of fetal heart rate. Severity of pain will be assessed using pain visual analogue scale (VAS) and intensity of anxiety will be examined by the state Spielberger inventory and VAS.